Compounds > Lonchocarpin
Page last updated: 2024-11-11

Lonchocarpin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lonchocarpine: has anti-bacterial, anti-inflammatory, antiproliferative, antioxidant, and antiepileptic activities; isolated from Abrus precatorius; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6283743
CHEMBL ID457644
CHEBI ID187208

Synonyms (16)

Synonym
lonchocarpin
LMPK12120012
NCGC00187466-02
CHEMBL457644
CHEBI:187208
(e)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)-3-phenylprop-2-en-1-one
31501-55-0
NCGC00187466-01
(e)-1-(5-hydroxy-2,2-dimethyl-2h-1-benzopyran-6-yl)-3-phenyl-2-propen-1-one
2-propen-1-one, 1-(5-hydroxy-2,2-dimethyl-2h-1-benzopyran-6-yl)-3-phenyl-, (e)-
lonchocarpine
DTXSID60185403
ncgc00187466-03!(e)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)-3-phenylprop-2-en-1-one
(e)-1-(5-hydroxy-2,2-dimethyl-2h-chromen-6-yl)-3-phenylprop-2-en-1-one
(2e)-1-(5-hydroxy-2,2-dimethyl-2h-1-benzopyran-6-yl)-3-phenyl-2-propen-1-one
AKOS040735087

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Furthermore, 5b could significantly suppress the progression of carrageenan-induced hind paw edema compared to indomethacin at a dosage of 10 mg/kg/day, and dose-dependently ameliorated the development of adjuvant-induced arthritis (AIA) validated by arthritic scores and H&E staining of joints."( Rational design, synthesis, and pharmacological properties of pyranochalcone derivatives as potent anti-inflammatory agents.
Cao, D; Chen, J; Chen, L; Deng, C; Li, X; Liang, X; Ma, L; Peng, A; Peng, F; Qiu, J; Ran, Y; Wang, G; Wei, Y; Xiang, M; Xie, C; Yang, Z; Ye, H, 2012)		0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
chalconesA ketone that is 1,3-diphenylpropenone (benzylideneacetophenone), ArCH=CH(=O)Ar, and its derivatives formed by substitution.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency8.42790.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency1.12200.00527.809829.0929AID588855
67.9K proteinVaccinia virusPotency12.58930.00018.4406100.0000AID720580
serine-protein kinase ATM isoform aHomo sapiens (human)Potency25.95610.707925.111941.2351AID504361; AID504362
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID388003Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by microdilution broth method2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Structure-activity relationship of antibacterial chalcones.
AID1192788Induction of NQO1 activity in mouse Hepa-1c1c7 cells assessed as induction ratio at 20 uM after 48 hr by NADPH-dependent MTT assay relative to control2015Bioorganic & medicinal chemistry letters, Mar-01, Volume: 25, Issue:5
Chemopreventive flavonoids from Millettia pulchra Kurz var-laxior (Dunn) Z.Wei (Yulangsan) function as Michael reaction acceptors.
AID1192790Cytotoxicity against mouse Hepa-1c1c7 cells assessed as cell viability at 20 uM after 10 mins2015Bioorganic & medicinal chemistry letters, Mar-01, Volume: 25, Issue:5
Chemopreventive flavonoids from Millettia pulchra Kurz var-laxior (Dunn) Z.Wei (Yulangsan) function as Michael reaction acceptors.
AID1227827Cytotoxicity against mouse BV2 cells assessed as reduction of cell viability at IC50 after 24 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jan-01, Volume: 25, Issue:1
Natural therapeutic agents for neurodegenerative diseases from a traditional herbal medicine Pongamia pinnata (L.) Pierre.
AID1290515Antileishmanial activity against intracellular amastigote stage of Leishmania amazonensis infected in human THP1 cells after 3 hrs by microplate based assay2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
Individual and combined antiparasitic effect of six plant metabolites against Leishmania amazonensis and Trypanosoma cruzi.
AID388001Antibacterial activity against Bacillus cereus ATCC 11778 after 24 hrs by microdilution broth method2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Structure-activity relationship of antibacterial chalcones.
AID1290516Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
Individual and combined antiparasitic effect of six plant metabolites against Leishmania amazonensis and Trypanosoma cruzi.
AID388002Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by microdilution broth method2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Structure-activity relationship of antibacterial chalcones.
AID1290517Selectivity index, ratio of CC50 for human THP1 cells to IC50 for Leishmania amazonensis2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
Individual and combined antiparasitic effect of six plant metabolites against Leishmania amazonensis and Trypanosoma cruzi.
AID388004Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by microdilution broth method2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Structure-activity relationship of antibacterial chalcones.
AID1290514Antiprotozoan activity against intracellular amastigote stage of Trypanosoma cruzi Tulahuen infected in human THP1 cells assessed as reduction in parasite viability after 48 hrs by microplate based assay2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
Individual and combined antiparasitic effect of six plant metabolites against Leishmania amazonensis and Trypanosoma cruzi.
AID1227826Anti-neuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay2015Bioorganic & medicinal chemistry letters, Jan-01, Volume: 25, Issue:1
Natural therapeutic agents for neurodegenerative diseases from a traditional herbal medicine Pongamia pinnata (L.) Pierre.
AID1290518Selectivity index, ratio of CC50 for human THP1 cells to IC50 for Trypanosoma cruzi Tulahuen2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
Individual and combined antiparasitic effect of six plant metabolites against Leishmania amazonensis and Trypanosoma cruzi.
AID666600Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 2 hrs prior to LPS-challenge measured after 22 hrs by Griess method relative to untreated control2012European journal of medicinal chemistry, Aug, Volume: 54Rational design, synthesis, and pharmacological properties of pyranochalcone derivatives as potent anti-inflammatory agents.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.25 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index5.33 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
4'-bromoflavone
4'-bromoflavone: structure in first source		2.1110
damnacanthal
damnacanthal: structure given in first source; isolated from the stem bark and roots of Morinda lucida; a selective inhibitor of p56(lck) tyrosine kinase activity		2.1310aldehyde;
monohydroxyanthraquinone
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		2.0710aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
phloretin
[no description available]		2.0410dihydrochalconesantineoplastic agent;
plant metabolite
benzonidazole
benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.		2.1310C-nitro compound;
imidazoles;
monocarboxylic acid amide		antiprotozoal drug
karanjin
karanjin: structure given in first source		2.5220extended flavonoid
betulonic acid
betulonic acid: isolated from Rush javanica; strucure in first source		2.1110triterpenoidanticoronaviral agent
isoliquiritigenin
[no description available]		2.0410chalconesantineoplastic agent;
biological pigment;
EC 1.14.18.1 (tyrosinase) inhibitor;
GABA modulator;
geroprotector;
metabolite;
NMDA receptor antagonist
formononetin
[no description available]		2.11104'-methoxyisoflavones;
7-hydroxyisoflavones		phytoestrogen;
plant metabolite
amphotericin b
Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.		2.1310antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
isobavachalcone
isobavachalcone: RN given for (E)-isomer; structure in first source. isobavachalcone : A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 4, 2' and 4' and a prenyl group at position 3'.		2.4820chalcones;
polyphenol		antibacterial agent;
metabolite;
platelet aggregation inhibitor
psi-baptigenin
pseudobaptigenin : A member of the class of 7-hydroxyisoflavones that is 7-hydroxyisoflavone and in which the phenyl group at position 3 is replaced by a 1,3-benzodioxol-5-yl group.		2.11107-hydroxyisoflavones;
benzodioxoles		antiprotozoal drug;
plant metabolite
4-hydroxycordoin
4-hydroxycordoin: antibacterial and anti-inflammatory from Lonchocarpus neuroscapha Benth. (Fabaceae); structure in first source. 4-hydroxycordoin : A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at position 4 and 2' and a (3-methylbut-2-en-1-yl)oxy group at position 4'. It has been isolated from Lonchocarpus neuroscapha.		2.0410aromatic ether;
chalcones;
polyphenol		anti-inflammatory agent;
antibacterial agent;
plant metabolite
4-hydroxylonchocarpin
4-hydroxylonchocarpin: structure in first source		2.7730
derricidin
derricidin: from Lonchocarpus sericeus; structure in first source		2.0410chalcones
isocordoin
isocordoin: a metabolite biotransformed from Morus nigra; structure in first source		2.0410chalcones
4-hydroxyderricin
4-hydroxyderricin: from Angelica keiskei; RN given refers to (E)-isomer; structure in first source		2.0410chalcones
Retusin 7-Methyl Ether
[no description available]		2.1110methoxyisoflavone
4-Methoxylonchocarpin
[no description available]		2.0710chalcones
5-methoxy-8,8-dimethyl-2-phenyl-4H,8H-pyrano[2,3-h]chromen-4-one
[no description available]		2.1110extended flavonoid
tetracycline
Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.		2.0410
ConditionIndicatedRelationship StrengthStudiesTrials
Adjuvant Arthritis
[description not available]		02.0710
Anasarca
[description not available]		02.0710
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		02.0710
Degenerative Diseases, Central Nervous System
[description not available]		02.1110
Neurodegenerative Diseases
Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.		02.1110
American Trypanosomiasis
[description not available]		02.1310
Leishmaniasis, American
[description not available]		02.1310
Chagas Disease
Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.		02.1310
Leishmaniasis, Cutaneous
An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.		02.1310
Innate Inflammatory Response
[description not available]		02.1510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		07.1510